一分钟看懂
这是一项关于Appendix Adenocarcinoma的II 期研究，登记的药物或干预包括Atezolizumab；Bevacizumab；Laboratory Biomarker Analysis；Pharmacological Study，当前状态为研究进行中，已停止招募。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Atezolizumab；Bevacizumab；Laboratory Biomarker Analysis；Pharmacological Study · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- M D Anderson Cancer Center · Houston
公开的入选条件
- * Signed informed consent form
- * Ability to comply with the study protocol, in the investigator's judgment
- * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radi
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L without granulocyte colony-stimulating factor support, obtained within 14 days prior to initiation of study treatment
- * Lymphocyte count \>= 0.5 x 10\^9/L, obtained within 14 days prior to initiation of study treatment
- * Platelet count \>= 100 x 10\^9/L without transfusion, obtained within 14 days prior to initiation of study treatment
- * White blood cell (WBC) count \>= 2500/ul, obtained within 14 days prior to initiation of study treatment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT03074513；登记信息更新于 2026-09-14。